Rudolph M. Navari

8.0k total citations
164 papers, 5.7k citations indexed

About

Rudolph M. Navari is a scholar working on Surgery, Physiology and Oncology. According to data from OpenAlex, Rudolph M. Navari has authored 164 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Surgery, 78 papers in Physiology and 25 papers in Oncology. Recurrent topics in Rudolph M. Navari's work include Nausea and vomiting management (131 papers), Anesthesia and Pain Management (74 papers) and Pathogenesis and Treatment of Hiccups (58 papers). Rudolph M. Navari is often cited by papers focused on Nausea and vomiting management (131 papers), Anesthesia and Pain Management (74 papers) and Pathogenesis and Treatment of Hiccups (58 papers). Rudolph M. Navari collaborates with scholars based in United States, Canada and South Africa. Rudolph M. Navari's co-authors include Matti Aapro, Sarah E. Gray, Lee S. Schwartzberg, Paul J. Hesketh, Richard J. Gralla, Patrick White, Charles L. Loprinzi, Lawrence H. Einhorn, Eric P. Winer and Bernardo L. Rapoport and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Rudolph M. Navari

156 papers receiving 5.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rudolph M. Navari United States 42 3.7k 2.1k 893 762 420 164 5.7k
Fausto Roila Italy 45 4.5k 1.2× 2.0k 1.0× 1.7k 1.9× 1.2k 1.6× 302 0.7× 135 7.9k
Jørn Herrstedt Denmark 42 3.6k 1.0× 2.4k 1.2× 3.4k 3.8× 1.0k 1.3× 517 1.2× 172 8.4k
Gurkirpal Singh United States 43 1.9k 0.5× 654 0.3× 525 0.6× 362 0.5× 504 1.2× 122 8.0k
Carlo DeAngelis Canada 34 1.4k 0.4× 528 0.3× 1.4k 1.6× 528 0.7× 317 0.8× 205 4.1k
Celeste Lindley United States 33 1.1k 0.3× 565 0.3× 1.5k 1.7× 621 0.8× 764 1.8× 90 5.1k
Paul J. Hesketh United States 51 8.3k 2.2× 3.9k 1.9× 2.4k 2.7× 1.4k 1.9× 598 1.4× 161 11.5k
Andrew Wilcock United Kingdom 35 906 0.2× 4.0k 2.0× 1.6k 1.8× 954 1.3× 1.1k 2.6× 138 7.3k
W. Lorenz Germany 39 900 0.2× 641 0.3× 669 0.7× 329 0.4× 1.6k 3.9× 277 5.2k
Wladimiro Jiménez Spain 63 5.8k 1.6× 1.1k 0.5× 451 0.5× 260 0.3× 1.4k 3.3× 307 15.9k
Paul D. Berk United States 42 2.1k 0.6× 1.3k 0.6× 684 0.8× 953 1.3× 1.5k 3.6× 123 6.2k

Countries citing papers authored by Rudolph M. Navari

Since Specialization
Citations

This map shows the geographic impact of Rudolph M. Navari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rudolph M. Navari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rudolph M. Navari more than expected).

Fields of papers citing papers by Rudolph M. Navari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rudolph M. Navari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rudolph M. Navari. The network helps show where Rudolph M. Navari may publish in the future.

Co-authorship network of co-authors of Rudolph M. Navari

This figure shows the co-authorship network connecting the top 25 collaborators of Rudolph M. Navari. A scholar is included among the top collaborators of Rudolph M. Navari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rudolph M. Navari. Rudolph M. Navari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Navari, Rudolph M., Naoki Inui, Hirotoshi Iihara, et al.. (2025). Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncology. 21(21). 2823–2833.
2.
Yeo, Winnie, Giampaolo Bianchini, Javier Cortés, et al.. (2025). Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncology. 21(10). 1261–1272.
3.
4.
Navari, Rudolph M., et al.. (2023). Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Advances in Therapy. 40(7). 3217–3226. 7 indexed citations
5.
Zelek, Laurent, Rudolph M. Navari, Matti Aapro, & Florian Scotté. (2023). Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Medicine. 12(15). 15769–15776. 8 indexed citations
6.
Schwartzberg, Lee S., Rudolph M. Navari, Kathryn J. Ruddy, et al.. (2023). Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Supportive Care in Cancer. 31(11). 654–654. 1 indexed citations
7.
Navari, Rudolph M., G. Binder, Alex Molassiotis, et al.. (2022). Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. The Oncologist. 28(3). 208–213. 7 indexed citations
8.
Navari, Rudolph M., et al.. (2021). Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis. Future Oncology. 17(23). 3027–3035. 13 indexed citations
9.
Navari, Rudolph M. & Eric Roeland. (2020). Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncology. 16(24). 1863–1872. 2 indexed citations
10.
Navari, Rudolph M.. (2019). The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opinion on Drug Safety. 18(12). 1127–1132. 3 indexed citations
11.
Navari, Rudolph M.. (2015). The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Drug Safety. 15(3). 343–356. 28 indexed citations
12.
Navari, Rudolph M.. (2015). Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Review of Anticancer Therapy. 15(10). 1127–1133. 11 indexed citations
13.
Alves, Nathan J., Matthew M. Champion, Jared F. Stefanick, et al.. (2013). Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site. Biomaterials. 34(22). 5700–5710. 29 indexed citations
14.
Walsh, Mark, Scott Thomas, E.P. Evans, et al.. (2011). Blood Component Therapy in Trauma Guided with the Utilization of the Perfusionist and Thromboelastography. Journal of ExtraCorporeal Technology. 43(3). 162–167. 29 indexed citations
15.
Navari, Rudolph M.. (2008). Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.. PubMed. 9(7). 774–85. 11 indexed citations
16.
Navari, Rudolph M.. (2004). Role of Neurokinin-1 Receptor Antagonists in Chemotherapy-Induced Emesis: Summary of Clinical Trials. Cancer Investigation. 22(4). 569–576. 12 indexed citations
17.
Navari, Rudolph M. & Jim M. Koeller. (2003). Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists. Annals of Pharmacotherapy. 37(9). 1276–1286. 79 indexed citations
18.
Pater, Joseph L., W. Lofters, Benny Zee, et al.. (1997). The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Annals of Oncology. 8(2). 181–185. 54 indexed citations
19.
20.
Navari, Rudolph M., Stefan Madajewicz, N. Anderson, et al.. (1995). Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.. Journal of Clinical Oncology. 13(9). 2408–2416. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fausto Roila Breakdown of academic impact, for papers by Jørn Herrstedt Breakdown of academic impact, for papers by Gurkirpal Singh Breakdown of academic impact, for papers by Carlo DeAngelis Breakdown of academic impact, for papers by Celeste Lindley Breakdown of academic impact, for papers by Paul J. Hesketh Breakdown of academic impact, for papers by Andrew Wilcock Breakdown of academic impact, for papers by W. Lorenz Breakdown of academic impact, for papers by Wladimiro Jiménez Breakdown of academic impact, for papers by Paul D. Berk
Rankless by CCL
2026